{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:45:20Z","timestamp":1791909920723,"version":"4.3.4"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2013,6,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 (<jats:sup>90<\/jats:sup>Y) \u2013ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients with CD20<jats:sup>+<\/jats:sup> stage III or IV FL with complete response (CR), unconfirmed CR (CRu), or partial response (PR) after first-line induction treatment were randomly assigned to <jats:sup>90<\/jats:sup>Y-ibritumomab consolidation therapy (rituximab 250 mg\/m<jats:sup>2<\/jats:sup> days \u22127 and 0, then <jats:sup>90<\/jats:sup>Y-ibritumomab 14.8 MBq\/kg day 0; maximum 1,184 MBq) or no further treatment (control). Primary end point was progression-free survival (PFS) from date of random assignment. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> For 409 patients available for analysis (<jats:sup>90<\/jats:sup>Y-ibritumomab, n = 207; control, n = 202), estimated 8-year overall PFS was 41% with <jats:sup>90<\/jats:sup>Y-ibritumomab versus 22% for control (hazard ratio [HR], 0.47; P &lt; .001). For patients in CR\/CRu after induction, 8-year PFS with <jats:sup>90<\/jats:sup>Y-ibritumomab was 48% versus 32% for control (HR, 0.61; P = .008), and for PR patients, it was 33% versus 10% (HR, 0.38; P &lt; .001). For <jats:sup>90<\/jats:sup>Y-ibritumomab consolidation, median PFS was 4.1 years (v 1.1 years for control; P &lt; .001). Median time to next treatment (TTNT) was 8.1 years for <jats:sup>90<\/jats:sup>Y-ibritumomab versus 3.0 years for control (P &lt; .001) with approximately 80% response rates to second-line therapy in either arm, including autologous stem-cell transplantation. No unexpected toxicities emerged during long-term follow-up. Estimated between-group 8-year overall survival rates were similar. Annualized incidence rate of myelodysplastic syndrome\/acute myeloblastic leukemia was 0.50% versus 0.07% in <jats:sup>90<\/jats:sup>Y-ibritumomab and control groups, respectively (P = .042). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> <jats:sup>90<\/jats:sup>Y-ibritumomab consolidation after achieving PR or CR\/CRu to induction confers 3-year benefit in median PFS with durable 19% PFS advantage at 8 years and improves TTNT by 5.1 years for patients with advanced FL. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2012.45.6400","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T01:36:41Z","timestamp":1364866601000},"page":"1977-1983","source":"Crossref","is-referenced-by-count":193,"title":["<sup>90<\/sup>Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial"],"prefix":"10.1200","volume":"31","author":[{"given":"Franck","family":"Morschhauser","sequence":"first","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achiel","family":"Van Hoof","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ama Z.S.","family":"Rohatiner","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Soubeyran","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Tilly","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Bischof-Delaloye","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim L.J.","family":"van Putten","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle W.","family":"Kylstra","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Hagenbeek","sequence":"additional","affiliation":[{"name":"Franck Morschhauser, Centre Hospitalier Universitaire, Lille; Gilles Salles, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite; Pierre Soubeyran, Institut Bergoni\u00e9, Bordeaux; Herve Tilly, Centre Henri Becquerel, Rouen, France; John Radford, The Christie National Health Service Foundation Trust and The University of Manchester, Manchester; Ama Z.S. Rohatiner, St Bartholomew's Hospital, London, United Kingdom; Achiel Van Hoof, University Hospital St Jan, Brugge, Belgium; Barbara Botto, Azienda Ospedaliera Citta..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma 2011 National Comprehensive Cancer Network (NCCN) version 2 http:\/\/www nccn org\/professionals\/physician_gls\/f_guidelines asp"},{"key":"B2","unstructured":"SEER Cancer Statistics, SEER Stat Fact Sheets: Lymphoma. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) http:\/\/seer.cancer.gov\/statfacts\/html\/lymph.html"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328358f602"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"B6","first-page":"CD003805","volume":"4","author":"Schulz H","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405078"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"B16","doi-asserted-by":"crossref","first-page":"iv88","DOI":"10.1093\/annonc\/mdr188","volume":"22","author":"Bachy E","year":"2011","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"B18","volume":"18","author":"Burnette BL","year":"2011","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2882"},{"key":"B22","volume-title":"Consolidation with 90Y ibritumomab tiuxetan (Zevalin) versus maintenance treatment with rituximab (MabThera).","author":"ClinicalTrials.gov"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2012.45.6400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:18:25Z","timestamp":1653520705000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2012.45.6400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,1]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013,6,1]]}},"alternative-id":["10.1200\/JCO.2012.45.6400"],"URL":"https:\/\/doi.org\/10.1200\/jco.2012.45.6400","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,1]]}}}